Who owns CTNM?
Institutional ownership of Contineum Therapeutics Inc. from Form 13F, Q2 2026
102 institutional managers reported holding Contineum Therapeutics Inc. (CTNM) in Form 13F filings for Q2 2026, with 30,545,688 shares worth $501M. The largest reported holder was Montanova Capital, LLC. Managers that filed both quarters cut a net 8,409 shares (-0.0%). 28 opened new positions and 15 sold out.
- Funds holding
- 102
- Value held
- $501M
- New / sold out
- 28 / 15
- Net shares, same filers
- -0.0%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of CTNM
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Montanova Capital, LLC | $46.6M | 9.3% | 2,841,334 | Unchanged |
| Jupiter Topco LLC | $44.8M | 9.0% | 2,734,836 | First report |
| BlackRock, Inc. | $33.8M | 6.8% | 2,064,345 | Added |
| Johnson & Johnson | $32.4M | 6.5% | 1,979,173 | Unchanged |
| Franklin Resources Inc | $30.1M | 6.0% | 1,839,227 | Unchanged |
| Balyasny Asset Management L.P. | $25.0M | 5.0% | 1,522,793 | Trimmed |
| Vanguard Capital Management LLC | $21.7M | 4.3% | 1,321,356 | Added |
| Perceptive Advisors LLC | $20.6M | 4.1% | 1,255,592 | Unchanged |
| FMR LLC | $17.0M | 3.4% | 1,040,130 | Added |
| Millennium Management LLC | $15.3M | 3.1% | 931,709 | Trimmed |
| Great Point Partners LLC | $15.1M | 3.0% | 921,481 | Added |
| Longaeva Partners L.P. | $13.3M | 2.7% | 812,757 | Added |
| Ikarian Capital, LLC | $13.2M | 2.6% | 807,874 | Unchanged |
| Sectoral Asset Management Inc | $11.9M | 2.4% | 727,587 | Unchanged |
| Geode Capital Management, LLC | $11.4M | 2.3% | 693,188 | Added |
| HHLR Advisors, LTD. | $11.0M | 2.2% | 669,337 | Unchanged |
| Red Tree Management, LLC | $10.5M | 2.1% | 638,158 | Unchanged |
| Versant Venture Management, LLC | $8.9M | 1.8% | 542,628 | Unchanged |
| Goldman Sachs Group Inc | $8.2M | 1.6% | 497,255 | Added |
| Boxer Capital Management, LLC | $8.1M | 1.6% | 494,000 | Unchanged |
| State Street Corp | $7.0M | 1.4% | 425,902 | Added |
| Citadel Advisors LLC | $6.5M | 1.3% | 396,354 | Added |
| Adage Capital Partners GP, L.l.c. | $5.4M | 1.1% | 328,000 | New |
| Silverarc Capital Management, LLC | $4.9M | 1.0% | 296,135 | Trimmed |
| ADAR1 Capital Management, LLC | $4.6M | 0.9% | 278,961 | Added |
Share of 13F holdings is each fund's shares as a share of the 30,545,688 CTNM shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- BlackRock, Inc. Added+$22.9M
- Geode Capital Management, LLC Added+$6.7M
- Adage Capital Partners GP, L.l.c. New+$5.4M
- State Street Corp Added+$5.3M
- Squadron Capital Management LLC New+$4.3M
- FMR LLC Added+$3.7M
- Northern Trust Corp Added+$3.5M
- Goldman Sachs Group Inc Added+$3.1M
- Vanguard Portfolio Management LLC New+$3.0M
- Great Point Partners LLC Added+$2.0M
Biggest sellers in Q2 2026
- Baker Bros. Advisors LP Sold out-$18.6M
- Ra Capital Management, L.p. Sold out-$16.9M
- Millennium Management LLC Trimmed-$9.9M
- Jones Hill Capital LP Sold out-$6.7M
- Susquehanna International Group, LLP Trimmed-$4.9M
- Balyasny Asset Management L.P. Trimmed-$2.7M
- Marshall Wace, LLP Trimmed-$1.8M
- UBS Group AG Trimmed-$1.6M
- Jane Street Group, LLC Sold out-$1.4M
- Point72 Asset Management, L.P. Trimmed-$969K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $83.8M and sold $71.9M; 32 added and 19 trimmed.
Schedule 13D and 13G filings on CTNM
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-05FMR LLC SCHEDULE 13G filed by Contineum Therapeutics Inc.Schedule 13G
- 2026-07-27BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2026-05-15BALYASNY ASSET MANAGEMENT L.P. SCHEDULE 13G filed by Contineum Therapeutics Inc.Schedule 13G
- 2026-04-17MILLENNIUM MANAGEMENT LLC SCHEDULE 13G filed by Contineum Therapeutics Inc.Schedule 13G
- 2026-02-17JANUS HENDERSON GROUP PLC SCHEDULE 13G filed by Contineum Therapeutics Inc.Schedule 13G
- 2026-02-17BALYASNY ASSET MANAGEMENT L.P. SCHEDULE 13G filed by Contineum Therapeutics Inc.Schedule 13G
- 2025-07-25RA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G filed by Contineum Therapeutics Inc.Schedule 13G
Questions about CTNM ownership
- Who owns CTNM stock?
- 102 institutional investment managers reported CTNM positions in their Form 13F filings for Q2 2026, holding 30,545,688 shares worth $501M in total. Montanova Capital, LLC reported the largest position.
- Are funds buying or selling CTNM?
- In Q2 2026, 28 managers opened new CTNM positions, 32 added, 19 trimmed and 15 sold out. Managers that filed in both quarters sold a net 8,409 shares.
- How current is this CTNM institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to CTNM by CUSIP. Options are left out. CTNM news and filings · CTNM insider trades · Top funds